CRISPR Therapeutics (NASDAQ:CRSP) was upgraded by Jefferies Financial Group from a “hold” rating to a “buy” rating in a report released on Wednesday, Analyst Price Targets reports. The brokerage currently has a $172.00 target price on the stock. Jefferies Financial Group’s target price points to a potential upside of 36.63% from the stock’s current price.

Several other research firms also recently weighed in on CRSP. JMP Securities initiated coverage on CRISPR Therapeutics in a report on Wednesday, March 10th. They set an “outperform” rating and a $160.00 price objective on the stock. Zacks Investment Research downgraded CRISPR Therapeutics from a “hold” rating to a “sell” rating and set a $177.00 target price on the stock. in a report on Monday, February 1st. The Goldman Sachs Group cut their target price on CRISPR Therapeutics from $193.00 to $189.00 and set a “neutral” rating on the stock in a report on Wednesday, February 17th. Needham & Company LLC reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 17th. Finally, Chardan Capital lifted their target price on CRISPR Therapeutics from $166.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, February 17th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $161.82.

Shares of CRSP stock opened at $125.89 on Wednesday. The stock’s fifty day moving average price is $121.07 and its two-hundred day moving average price is $134.86. The company has a market cap of $9.50 billion, a PE ratio of -38.62 and a beta of 2.37. CRISPR Therapeutics has a fifty-two week low of $46.84 and a fifty-two week high of $220.20.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, February 15th. The company reported ($1.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.27) by ($0.23). CRISPR Therapeutics had a negative net margin of 273.10% and a negative return on equity of 20.72%. The firm had revenue of $0.37 million for the quarter, compared to analyst estimates of $4.69 million. Analysts expect that CRISPR Therapeutics will post -4.97 EPS for the current fiscal year.

In other CRISPR Therapeutics news, Director Bradley J. Phd Bolzon sold 30,374 shares of the business’s stock in a transaction that occurred on Monday, March 22nd. The stock was sold at an average price of $132.37, for a total transaction of $4,020,606.38. Following the completion of the sale, the director now directly owns 57,149 shares of the company’s stock, valued at approximately $7,564,813.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 17.10% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in CRSP. Norges Bank purchased a new position in shares of CRISPR Therapeutics in the 4th quarter worth approximately $86,215,000. Morgan Stanley lifted its stake in CRISPR Therapeutics by 45.3% in the fourth quarter. Morgan Stanley now owns 731,427 shares of the company’s stock valued at $111,988,000 after purchasing an additional 227,927 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in CRISPR Therapeutics by 8.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,774,436 shares of the company’s stock valued at $271,684,000 after purchasing an additional 143,504 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its stake in CRISPR Therapeutics by 3.8% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,836,823 shares of the company’s stock valued at $587,456,000 after purchasing an additional 139,156 shares during the last quarter. Finally, Hitchwood Capital Management LP purchased a new position in CRISPR Therapeutics in the fourth quarter valued at approximately $11,483,000. Hedge funds and other institutional investors own 66.43% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.

See Also: Bull Market

Analyst Recommendations for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.